Basic Profile / Key Facts
Drug Category
- Anticoagulants
- Antiplatelet Agents
Dosage Forms
Description
Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) lIb/IlIa receptor of human platelets and inhibits platelet aggregation.
Indications
For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina
Pharmacology
Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.
Mechanism of Action
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production
Contraindications
Not Available
Drug Interactions
Not Available
|
